Boston, MANCT05759468Now EnrollingIRB Ready

Type2diabetes Clinical Trial in Boston, MA

Access cutting-edge type2diabetes treatment through this phase 2 clinical trial at a research site in Boston. Study-provided care at no cost to qualified participants.

Sponsored by Brigham and Women's Hospital

Quick Self-Assessment

See if you qualify for this Boston location

Preparing your pre-screening questions…

Expert Care in Boston

Access type2diabetes specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related type2diabetes treatment provided free

Apply for This Boston Location

Check if you qualify for this type2diabetes clinical trial in Boston, MA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Boston

    Convenient for MA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Boston site if eligible
  4. 4Begin participation

About This Type2diabetes Study in Boston

A phase 2a trial randomized, double-blind, placebo-controlled, parallel group trial to determine whether NMN administration improves DKD, as indicated by a significantly greater reduction in UACR compared with placebo administration. Eligible participants will be randomized to receive either 1000 mg NMN or placebo twice daily.

Sponsor: Brigham and Women's Hospital

Who Can Participate

Inclusion Criteria

A man or a postmenopausal woman (complete cessation of menses for one or more years and /or FSH \> 20 U/L), 30 years or older
Has type 1 or type 2 diabetes mellitus, as indicated by any of the following:
Self-report of type 1 or type 2 diabetes plus the use of a prescribed medication.
ICD-10 code for type 1 or type 2 diabetes plus current use of a medication in the electronic medical record.
HbA1c \>6.4%; or 2 fasting glucose \> 125 mg/dL
Has an average of two or more morning UACR equal to or above 100mg/g creatinine each of which must be equal to or greater than 60 mg / g creatinine with at least one UACR value measured during the screening visit. a. Recent UACR value in the medical record within the preceding 3 months prior to screening is acceptable.
If type 2 diabetic and UACR is \> 300 mg/g creatinine, must be currently using an ACE inhibitor or an ARB or a SGLT2 inhibitor.
eGFR \> 25 mL/ min / 1.73 m2
Hemoglobin A1c \<10%
Able to speak English or Spanish or Haitian Creole
Willing and able to provide written informed consent
In addition, female participants must Not be pregnant and not planning to become pregnant over the next 6 months.

Exclusion Criteria

Fasting morning UACR \> 5,000 mg/ g creatinine
Other laboratory abnormalities:
Has AST or ALT \> 3 times the upper limit of normal
eGFR \< 25 mL/ min / 1.73 m2
Hematocrit \< 0.34 or \> 0.50 L/L
A major adverse cardiovascular event in preceding 3 months
Participation in an investigational trial to evaluate pharmaceuticals or biologics within the past 3 months or 5 half-lives, whichever is shorter
Current alcohol or substance use disorder or dependence (DSM 5 criteria).
Major depressive disorder, bipolar disorder, schizophrenia, or current psychotic symptoms or behavioral problems that could interfere with study procedures.
An acute illness, including COVID-19, requiring hospitalization within the past 3 months or any acute illness, including COVID-19, within the past month.
Has a history of anaphylaxis from vitamin B3 derivatives
BMI \> 42.5 kg/ m2
If patient has a confirmed diagnosis of type 3 diabetes, or gestational diabetes.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Boston?

Yes, this clinical trial (NCT05759468) has an active research site in Boston, MA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Type2diabetes Treatment Options in Boston, MA

If you're searching for type2diabetes treatment options in Boston, MA, this clinical trial (NCT05759468) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Boston research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced type2diabetes specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all type2diabetes clinical trials near you to find additional studies recruiting in your area.

More Pulmonary Embolism Trials in Boston, MA

See all pulmonary embolism clinical trials recruiting in Boston — not just this study.

Browse Pulmonary Embolism Trials in Boston →

Browse More Trials by Condition

Pulmonary Embolism TrialsEssential Tremor TrialsAll Conditions →

Ready to Join in Boston?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Boston, MA